Effects of baseline lactate dehydrogenase (LDH), interferon gamma (IFN-g) expression, and tumor mutational burden (TMB) on treatment response to first-line atezolizumab (A) + vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation–positive advanced melanoma.

Caroline Robert,Karl D. Lewis,Paolo Antonio Ascierto,Rodrigo Ramella Munhoz,Gabriella Liszkay,Luis de la Cruz-Merino,Judit Olah,Paola Queirolo,Jacek Mackiewicz,Ivor Caro,Kalpit Shah,Harper Forbes,Haocheng Li,Christian Hertig,Yibing Yan,Edward Francis Mckenna,Ralf Gutzmer,Grant A. McArthur

user-6073b1344c775e0497f43bf9（2021）

引用 0|浏览21

暂无评分

摘要

9523Background: The phase 3 IMspire150 study showed that first-line A+V+C improved investigator-assessed PFS vs placebo (P)+V+C in BRAFV600E/K mutation–positive advanced melanoma (hazard ratio 0.78...

查看译文

关键词

Cobimetinib,Vemurafenib,Atezolizumab,Lactate dehydrogenase,Interferon gamma,Cancer research,Mutation,Medicine,First line,Treatment response

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要